The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain
Open accessAbstract
Low-dose naltrexone (LDN) has been demonstrated to reduce symptom severity in conditions such as fibromyalgia, Crohn's disease, multiple sclerosis, and complex regional pain syndrome. We review the evidence that LDN may operate as a novel anti-inflammatory agent in the central nervous system, via action on microglial cells. These effects may be unique to low dosages of naltrexone and appear to be entirely independent from naltrexone's better-known activity on opioid receptors. As a daily oral therapy, LDN is inexpensive and well-tolerated. Despite initial promise of efficacy, the use of LDN for chronic disorders is still highly experimental. Published trials have low sample sizes, and few replications have been performed. We cover the typical usage of LDN in clinical trials, caveats to using the medication, and recommendations for future research and clinical work. LDN may represent one of the first glial cell modulators to be used for the management of chronic pain disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Twenty years of research on cytokine-induced sickness behavior
Dantzer, R., & Kelley, K. W. (2007) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2006.09.006 · Cited by 1,420
Cytokine-induced sickness behavior
Kelley, K. W., Bluthé, R.-M., Dantzer, R., Zhou, J.-H., Shen, W.-H., Johnson, R. W., & Broussard, S. R. (2003) · Brain, Behavior, and Immunity · doi:10.1016/s0889-1591(02)00077-6 · Cited by 716
Immune–neural connections: how the immune system’s response to infectious agents influences behavior
McCusker, R. H., & Kelley, K. W. (2013) · Journal of Experimental Biology · doi:10.1242/jeb.073411 · Cited by 429
Results of a phase II placebo-controlled randomized trial of minocycline in acute spinal cord injury
Casha, S., Zygun, D., McGowan, M. D., Bains, I., Yong, V. W., & John Hurlbert, R. (2012) · Brain · doi:10.1093/brain/aws072 · Cited by 408
Hutchinson, M. R., Zhang, Y., Brown, K., Coats, B. D., Shridhar, M., Sholar, P. W., Patel, S. J., Crysdale, N. Y., Harrison, J. A., Maier, S. F., et al. (2008) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2008.06321.x · Cited by 397
Liu, B., Du, L., & Hong, J.-S. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)39275-4 · Cited by 347 · cited 1×
“in the brain and spinal cord is inhibited [23].”
BackgroundThe biology of the opioid growth factor receptor (OGFr)
Zagon, I. (2002) · Brain Research Reviews · doi:10.1016/s0165-0173(01)00160-6 · Cited by 328
Watkins, L. R., Hutchinson, M. R., Ledeboer, A., Wieseler-Frank, J., Milligan, E. D., & Maier, S. F. (2007) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2006.10.011 · Cited by 326
Clauw, D. J., Arnold, L. M., & McCarberg, B. H. (2011) · Mayo Clinic Proceedings · doi:10.4065/mcp.2011.0206 · Cited by 303
Therapy for Lyme arthritis: Strategies for the treatment of antibiotic‐refractory arthritis
Steere, A. C., & Angelis, S. M. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22131 · Cited by 244
Cited by
Witkiewitz, K., Vowles, K. E., McCallion, E., Frohe, T., Kirouac, M., & Maisto, S. A. (2015) · Addiction · doi:10.1111/add.12964 · Cited by 99
Pain in an era of armed conflicts: prevention and treatment for warfighters and civilian casualties
George, E., Elman, I., Becerra, L., Berg, S., & Borsook, D. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.04.002 · Cited by 18
Dara, P., Farooqui, Z., Mwale, F., Choe, C., van Wijnen, A. J., & Im, H.-J. (2023) · Biomedicines · doi:10.3390/biomedicines11061620 · Cited by 15
Metadata
- Authors
- Younger, J., Parkitny, L., & McLain, D.
- Venue
- Clinical Rheumatology
- Published
- 2014-02-15
- Volume
- 33
- Issue
- 4
- Pages
- 451-459
- ISSN
- 0770-3198 (ISSN-L)
- 1434-9949
- OpenAlex
- W2165305033
- Cited by
- 277
- References
- 47
- FWCI
- 7.39
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. https://app.cochat.ai/papers/10.1007/s10067-014-2517-2
- The paper
- Younger, J., Parkitny, L., & McLain, D. (2014). The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clinical Rheumatology. https://doi.org/10.1007/s10067-014-2517-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.